Comments
Commented by André Will-Laudien on November 7th, 2025 | 07:50 CET
Fact check: After the correction comes the next rally! Ups and downs for Almonty, Aixtron, and Deutsche Pfandbriefbank
Zigzag! Buy, sell, buy again! What wild volatility we are seeing on the trading board! Palantir delivers dream numbers, exceeding analysts' estimates by 10%, only to drop 20% after a brief rally. Traders have a saying for this: "Buy the rumor, sell the fact." Indeed, this kind of market behavior is often seen around earnings releases. In the case of Almonty, the stock surged an explosive 700% in just eight months, only to lose 40% in the subsequent correction. For flexible investors, it is worth taking a closer look and not losing sight of the fundamentals. Here are a few ideas for rocking the boat or tucking stocks away à la Kostolany!
Read
Commented by Armin Schulz on November 7th, 2025 | 07:05 CET
BYD and Graphano Energy are driving the energy storage revolution - even Nordex is benefiting indirectly
The energy landscape is undergoing radical change. The key no longer lies solely in the generation of green electricity, but in its intelligent storage and use. Electric vehicles are mutating into rolling power tanks that can stabilize grids, while extensive stationary storage facilities compensate for the fluctuating feed-in from wind and solar power. This revolution opens up massive savings potential for consumers and reduces the need for expensive grid upgrades. We take a look at whether BYD, Graphano Energy, and Nordex can benefit from this booming ecosystem.
Read
Commented by Fabian Lorenz on November 7th, 2025 | 07:00 CET
Takeover battle between Novo Nordisk and Pfizer! Is BioNxt Solutions the next target?
Who will acquire Metsera? That is currently the subject of dispute between Novo Nordisk and Pfizer. Both pharma giants are seeking access to a new generation of metabolic therapies through the acquisition - treatments that have the potential to transform the billion-dollar market for obesity and diabetes care. Novo Nordisk views Metsera's drug pipeline as a complement to its GLP-1-based preparations, while Pfizer is trying to finally gain a foothold in the market after several setbacks. The takeover battle illustrates that big pharma companies are willing to dig deep into their pockets for innovations. This makes BioNxt Solutions a potential takeover candidate. The Company is not only working on innovations in the field of multiple sclerosis and obesity, but on an entire platform technology.
Read
Commented by Armin Schulz on November 6th, 2025 | 07:55 CET
Take advantage of setbacks among industry leaders: A strategic entry into Almonty Industries, Rheinmetall, and D-Wave Quantum
During a phase of global market corrections, which has now also reached the US markets, true investor quality becomes evident. While weak hands see volatility as a threat, strategists recognize it as a valuable opportunity: the chance to position robust companies with clear competitive advantages and long-term growth trajectories at temporarily reduced prices. This pattern of strategic entries following setbacks among industry leaders is currently particularly evident at Almonty Industries, Rheinmetall, and D-Wave Quantum.
Read
Commented by André Will-Laudien on November 6th, 2025 | 07:10 CET
Novo Nordisk calculating carefully, Evotec facing potential takeover? Clinical trial and up-listing at Vidac!
The stock market is showing some turbulence in the biotech sector. Unlike the big growth stocks on the NASDAQ, there is still urgent catching-up to do here. Some figures, such as those from Novo Nordisk and Evotec, still give reason for concern. The situation is quite different at Vidac Pharma, where an up-listing to the primary market is on the horizon and a clinical trial is about to begin! Plenty of material for investors' dreams to grow. We calculate where an investment is worthwhile!
Read
Commented by Carsten Mainitz on November 6th, 2025 | 07:05 CET
Totally underestimated! These are the secret winners of the AI and energy revolution: Power Metallic Mines, Aixtron, and Siemens Energy!
Forget most of the hyped stocks in the AI and tech space. The most significant gains in the current tech and energy transition boom come - not from the diggers, but from the suppliers - just like during the Gold Rush in the 19th century. While billions are being poured into the hunt for digital gold (artificial intelligence) and green gold (renewable energy), the (emerging) raw material producers, specialized machinery manufacturers, and infrastructure providers are the ones benefiting most. We show you the overlooked profiteers of the boom!
Read
Commented by Fabian Lorenz on November 6th, 2025 | 07:00 CET
Does Germany have a drone problem? Hensoldt, TKMS, Helsing, and NEO Battery Materials!
Drone alerts at German and European airports! At the same time, criticism of Germany's defense policy is growing louder. Is the federal government investing too much in tanks and other heavy equipment and too little in drones and counter-drone systems? This opinion is shared not only by the head of Germany's new drone star, Helsing, but also by several other experts. The situation is quite different in the rest of the world, where demand for drones is rising significantly. NEO Battery Materials is also benefiting from this trend. The Company recently secured an existing factory in South Korea for the production of high-performance batteries, and the first million-dollar orders are already in place. And what is TKMS doing? Its share price has slipped in recent days. Could large orders bring new momentum?
Read
Commented by Armin Schulz on November 5th, 2025 | 07:20 CET
Gold on the verge of another record high? We take a closer look at Barrick Mining, LAURION Mineral Exploration, and Newmont
Gold is experiencing a historic upward trend. After briefly testing the magical USD 4,000 mark during the recent pullback, the price is consolidating at a high level and gathering momentum for the next surge. Driven by geopolitical tensions, a weakening USD, and continued buying sprees by central banks, new record highs appear increasingly likely. In this tense but lucrative market environment, three players with promising potential are positioning themselves: Barrick Mining, LAURION Mineral Exploration, and Newmont.
Read
Commented by André Will-Laudien on November 5th, 2025 | 07:15 CET
Money or gold – Where can investors expect another 150% return? ESG-compliant with RE Royalties, Deutsche Bank, PayPal, or Fiserv?
Gold continues to fascinate as a scarce and value-preserving asset. However, its extraction often comes with significant environmental and social challenges, making the label "sustainable" difficult to apply. Money, on the other hand, especially in the form of cash or digital currency, is intangible and based on trust; in modern times, its sustainability is defined by its use in ESG-compliant investments. And these are diverse! With its "Green Deal," the EU is driving a comprehensive transformation and directing capital toward sustainable technologies and projects through support programs and ESG regulations. This is particularly relevant for institutional investors, who are increasingly required to consider climate risks and social responsibility. Much of this capital flows into green infrastructure and technological innovation. Private investors, meanwhile, have green investments on their radar, though the primary focus here remains on returns. Let's dive into the world of financiers.
Read
Commented by Fabian Lorenz on November 5th, 2025 | 07:10 CET
Millions for BioNTech and Evotec! But drug development is costly! Is NetraMark the next takeover target?
NetraMark scores again. The Company's AI has convinced yet another biopharma company and is increasingly shaping up as a potential takeover target. The new client will use NetraAI to optimize its clinical trial, cutting both time and costs. The high expense of drug development is clear: BioNTech invested EUR 565 million into its pipeline last quarter. However, the German biotech leader can afford this thanks to billions in its coffers. Analysts still recommend buying the stock. By contrast, even a million-dollar payment from a partner could not give Evotec shares any real momentum. Could today’s figures finally spark a turnaround?
Read